Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Pro members get actionable news alerts up to 30 minutes before other traders — Get our lowest prices
Pro members get actionable news alerts up to 30 minutes before other traders — Get our lowest prices
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Enlivex Therapeutics Ltd has a consensus price target of $9.5 based on the ratings of 2 analysts. The high is $13 issued by EF Hutton on August 27, 2024. The low is $6 issued by HC Wainwright & Co. on June 11, 2024. The 3 most-recent analyst ratings were released by EF Hutton, HC Wainwright & Co., and HC Wainwright & Co. on August 27, 2024, June 11, 2024, and April 23, 2024, respectively. With an average price target of $8.67 between EF Hutton, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 604.61% upside for Enlivex Therapeutics Ltd from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Enlivex Therapeutics (NASDAQ:ENLV) was reported by EF Hutton on August 27, 2024. The analyst firm set a price target for $13.00 expecting ENLV to rise to within 12 months (a possible 956.91% upside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for Enlivex Therapeutics (NASDAQ:ENLV) was provided by EF Hutton, and Enlivex Therapeutics initiated their buy rating.
There is no last upgrade for Enlivex Therapeutics
There is no last downgrade for Enlivex Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enlivex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enlivex Therapeutics was filed on August 27, 2024 so you should expect the next rating to be made available sometime around August 27, 2025.
While ratings are subjective and will change, the latest Enlivex Therapeutics (ENLV) rating was a initiated with a price target of $0.00 to $13.00. The current price Enlivex Therapeutics (ENLV) is trading at is $1.23, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.